Markets
Immuron Limited (IMRN)
IMRNNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.8800
+0.0614 (+7.50%) today
Closed, Nov 9, 4:00 PM ET
+7.50% 1D
- Market cap
- $7.26m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.6765 to $1.99
- Average volume
- 2.57m
- Previous close
- $0.8186
Financials
No quarterly figures from the source.
News
8 latest- Immuron Limited Announces Strategic Reset to Partner Clinical Assets and Reports FY26 Global Sales Revenue of $7.7mFintel · Oct 28, 2026
- Immuron Limited Announces Q1 Global Sales of AUD$2.2 millionFintel · Oct 27, 2026
- Immuron Limited Decreases ATM Offering Program Limit to $2,006,769Fintel · Oct 23, 2026
- Immuron Reports Phase 2 Travelan Results Published In Scientific Reports; Stock Down RTTNews · Oct 13, 2026
- Immuron To Launch PROIBS In U.S. After Australia Debut; Pre-market Shares Up RTTNews · Sep 4, 2026
- Immuron FY26 Revenue Rises 6% As Net Loss Narrows And Cash Surges RTTNews · Aug 28, 2026
- Immuron FY26 Sales Rise 6%, Marks Fourth Consecutive Quarter Of Growth RTTNews · Jul 16, 2026
- Immuron: FDA Approves IND Application For IMM-529 RTTNews · Nov 5, 2025
The company
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- Australia and South Pacific
- Website
- immuron.com.au
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.